CN1165764C - 抗psma抗体或其抗原结合部分，以及它们的用途 - Google Patents

抗psma抗体或其抗原结合部分，以及它们的用途 Download PDF

Info

Publication number
CN1165764C
CN1165764C CNB97197912XA CN97197912A CN1165764C CN 1165764 C CN1165764 C CN 1165764C CN B97197912X A CNB97197912X A CN B97197912XA CN 97197912 A CN97197912 A CN 97197912A CN 1165764 C CN1165764 C CN 1165764C
Authority
CN
China
Prior art keywords
antigen
binding portion
antibody
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB97197912XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1244921A (zh
Inventor
Nh
N·H·邦德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26695548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1165764(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Publication of CN1244921A publication Critical patent/CN1244921A/zh
Application granted granted Critical
Publication of CN1165764C publication Critical patent/CN1165764C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB97197912XA 1996-07-18 1997-07-17 抗psma抗体或其抗原结合部分，以及它们的用途 Expired - Lifetime CN1165764C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2212596P 1996-07-18 1996-07-18
US60/022,125 1996-07-18
US08/838,682 1997-04-09
US08/838,682 US6107090A (en) 1996-05-06 1997-04-09 Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100544223A Division CN100344970C (zh) 1996-07-18 1997-07-17 结合前列腺特异性膜抗原胞外域的抗体或其抗原结合部分、包含它们的试剂盒及其用途

Publications (2)

Publication Number Publication Date
CN1244921A CN1244921A (zh) 2000-02-16
CN1165764C true CN1165764C (zh) 2004-09-08

Family

ID=26695548

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB97197912XA Expired - Lifetime CN1165764C (zh) 1996-07-18 1997-07-17 抗psma抗体或其抗原结合部分，以及它们的用途
CNB2004100544223A Expired - Lifetime CN100344970C (zh) 1996-07-18 1997-07-17 结合前列腺特异性膜抗原胞外域的抗体或其抗原结合部分、包含它们的试剂盒及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB2004100544223A Expired - Lifetime CN100344970C (zh) 1996-07-18 1997-07-17 结合前列腺特异性膜抗原胞外域的抗体或其抗原结合部分、包含它们的试剂盒及其用途

Country Status (15)

Country Link
US (4) US6107090A (enExample)
EP (2) EP0956506B1 (enExample)
JP (2) JP4503102B2 (enExample)
CN (2) CN1165764C (enExample)
AT (1) ATE319089T1 (enExample)
AU (1) AU733544C (enExample)
BR (1) BR9710487A (enExample)
CA (1) CA2261018C (enExample)
DE (1) DE69735368T2 (enExample)
EA (2) EA200400179A1 (enExample)
ES (1) ES2255723T3 (enExample)
IL (2) IL127979A0 (enExample)
NZ (2) NZ333683A (enExample)
PT (1) PT956506E (enExample)
WO (1) WO1998003873A1 (enExample)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US7070782B1 (en) 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
US6953668B1 (en) 1992-11-05 2005-10-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US6569432B1 (en) * 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
JP2001526522A (ja) 1995-02-24 2001-12-18 スローン−ケタリング・インスティテュート・フォー・キャンサー・リサーチ 前立腺特異的膜抗原およびその使用
US20040253246A1 (en) * 1996-02-23 2004-12-16 Israeli Ron S. Prostate-specific membrane antigen and uses thereof
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6962981B1 (en) * 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6150508A (en) * 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US20060269532A1 (en) * 1997-02-25 2006-11-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6759515B1 (en) * 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20060024301A1 (en) * 1997-02-25 2006-02-02 Corixa Corporation Prostate-specific polypeptides and fusion polypeptides thereof
US6207805B1 (en) * 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US6232287B1 (en) * 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US6200765B1 (en) 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer
FR2791573B1 (fr) * 1999-03-30 2003-04-11 Pf Medicament Utilisation d'un extrait de serenoa repens pour la fabrication d'un medicament destine au traitement du cancer de la prostate
EP1710256A1 (en) * 1999-07-29 2006-10-11 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen
DE60031279T2 (de) * 1999-07-29 2007-05-16 Medarex, Inc. Humane monoklonale antikörper gegen prostata spezifisches membranantigen
AU7351800A (en) * 1999-09-13 2001-04-17 Neil H. Bander A method for isolation of prostatic epithelial cells from semen
US20080153119A1 (en) * 1999-09-24 2008-06-26 Schebo Biotech Ag Detecting the presence of pyruvate kinase isoenzyme in feces
CA2399293C (en) 2000-02-08 2012-01-03 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US6379550B1 (en) * 2000-07-24 2002-04-30 Health Research, Inc. Method for detecting PSA and its molecular forms using thiophilic gel
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
AU2002239403A1 (en) 2000-12-01 2002-06-11 The Johns Hopkins University Tissue specific prodrugs
US20030007974A1 (en) * 2001-05-30 2003-01-09 Nanus David M. Endopeptidase/anti-PSMA antibody fusion proteins for treatment of cancer
JP4619651B2 (ja) * 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
AU2002359244A1 (en) * 2001-09-05 2003-04-28 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Imaging the activity of extracellular proteases in cells using mutant anthrax toxin protective antigens that are cleaved by specific extracellular proteases
MXPA03012022A (es) * 2001-09-20 2005-07-01 Cornell Res Foundation Inc Metodos y composiciones para tratar o prevenir padecimientos de la piel, utilizando agentes de enlace especificos para el antigeno de membrana especifico de prostata.
EP1432447A2 (en) * 2001-09-27 2004-06-30 The Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
US20040161776A1 (en) * 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US20050215472A1 (en) * 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7767803B2 (en) * 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
JP4827411B2 (ja) 2002-07-15 2011-11-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 陰イオン性リン脂質およびアミノリン脂質に結合する選択された抗体およびデュラマイシンペプチド、ならびにウイルス感染の処置におけるそれらの使用
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
DE60323677D1 (de) * 2003-01-10 2008-10-30 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
EP2336189A1 (en) * 2003-01-28 2011-06-22 Proscan RX Pharma Prostate cancer diagnosis and treatment
WO2005094882A1 (en) * 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US20080241262A1 (en) * 2004-03-29 2008-10-02 The University Of Houston System Nanoshells and Discrete Polymer-Coated Nanoshells, Methods For Making and Using Same
EP1756166A4 (en) * 2004-04-19 2008-08-27 Proscan Rx Pharma DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
US20080045865A1 (en) * 2004-11-12 2008-02-21 Hanoch Kislev Nanoparticle Mediated Ultrasound Therapy and Diagnostic Imaging
EP1864134A4 (en) * 2005-02-07 2010-10-20 Univ Columbia METHOD FOR TREATING OR PREVENTING HORMONRESISTENT PROSTATE CANCER USING PROTOCADHERINE PC SPECIFIC SIRNA OR OTHER INHIBITORS OF PROTOCADHERINE PC EXPRESSION OR ACTIVITY
CA2598454C (en) * 2005-02-18 2013-04-09 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
PL1851250T3 (pl) * 2005-02-18 2012-10-31 Squibb & Sons Llc Ludzkie przeciwciało monoklonalne przeciwko antygenowi błony komórkowej komórek prostaty (PSMA)
EP1863828A4 (en) * 2005-03-07 2010-10-13 Archemix Corp STABILIZED APTAMERS FOR PSMA AND THEIR USE AS PROSTATE ACID THERAPEUTICS
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
US7736647B2 (en) * 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
EP1912677B1 (en) * 2005-06-20 2013-10-02 Psma Development Company, L.L.C. PSMA antibody-drug conjugates
BRPI0617549A2 (pt) * 2005-09-26 2011-07-26 Medarex Inc anticorpo monoclonal humano isolado, anticorpo monoclonal humano isolado ou uma porÇço ligante ao antÍgeno do mesmo, composiÇço, imunoconjugado, molÉcula de Ácido nuclÉico isolada, vetor de expressço, cÉlula hospedeira, mÉtodo para preparar um anticorpo anti-cd70, mÉtodo para tratar ou prevenir uma doenÇa, mÉtodo para tratar uma doenÇa autoimune em um indivÍduo, mÉtodo para tratar uma inflamaÇço em um indivÍduo, mÉtodo para tratar uma infecÇço viral em um indivÍduo, anticorpo ou porÇço ligante ao antÍgeno do mesmo e uso de um anticorpo ou de uma porÇço ligante ao antÍgeno do mesmo
SI2532681T1 (sl) * 2005-12-20 2015-03-31 Sbi Biotech Co., Ltd. Protitelo proti-ILT7
ES2673822T3 (es) * 2006-07-18 2018-06-25 Sanofi Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer
EP2097534A4 (en) * 2006-12-14 2010-05-12 Medarex Inc HUMAN ANTIBODIES BINDING TO CD70 AND USES THEREOF
US20090029408A1 (en) * 2007-07-25 2009-01-29 Wyeth Methods for Characterizing Cell Proximity
WO2009046294A2 (en) 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
US20110189093A1 (en) * 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
PT2326350E (pt) 2008-09-08 2013-12-10 Psma Dev Company L L C Compostos para matar células cancerosas resistentes a taxano, que expressam psma
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
PL3939617T3 (pl) 2009-02-13 2025-03-17 Immunomedics, Inc. Związki pośrednie do wytwarzania koniugatów z wiązaniem rozszczepialnym wewnątrzkomórkowo
ES2712732T3 (es) 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
CA2769444A1 (en) 2009-05-19 2010-11-25 Aic Blab Company Composite current collector and methods therefor
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
AU2010325969B2 (en) 2009-12-02 2016-10-20 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
WO2011068845A1 (en) 2009-12-02 2011-06-09 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
PL2552959T3 (pl) 2010-03-26 2017-08-31 Memorial Sloan-Kettering Cancer Center Przeciwciała przeciwko MUC16 i metody stosowania
JP5702944B2 (ja) * 2010-03-31 2015-04-15 独立行政法人国立がん研究センター バイオマーカー
WO2011133555A2 (en) 2010-04-20 2011-10-27 The Research Foundation Of State University Of New York Compositions and methods for inhibiting matrix metalloproteinase (mmp)-mediated cell migration
JP6145404B2 (ja) * 2010-05-07 2017-06-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エクスビボでの細胞の検出のための診断的方法
WO2012075173A2 (en) 2010-12-01 2012-06-07 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
WO2012106368A2 (en) 2011-01-31 2012-08-09 The Regents Of The University Of California Methods for inhibiting prostate cancer
US8314566B2 (en) * 2011-02-22 2012-11-20 Quarkstar Llc Solid state lamp using light emitting strips
WO2012151199A1 (en) 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
MX363116B (es) 2012-06-07 2019-03-11 Ambrx Inc Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.
AU2013274078A1 (en) 2012-06-14 2015-01-29 Ambrx, Inc. Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
JP6340006B2 (ja) * 2012-10-05 2018-06-06 コーネル ユニヴァーシティー アンドロゲン抑制、前立腺特異的膜抗原、および条件的に増大した脆弱性の概念
AU2013328580B2 (en) 2012-10-12 2016-01-21 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
BR112015013444B1 (pt) 2012-12-13 2022-11-01 Immunomedics, Inc Uso de um imunoconjugado
US11242399B2 (en) 2013-02-19 2022-02-08 Adienne S.A. Anti-CD26 antibodies
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
BR112015022123B1 (pt) 2013-03-15 2022-08-09 Intrinsic Lifesciences, Llc Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit
JP6908964B2 (ja) 2013-10-18 2021-07-28 ピーエスエムエー ディベロップメント カンパニー，エルエルシー Ｐｓｍａリガンドコンジュゲートによる併用療法
WO2015073896A2 (en) 2013-11-15 2015-05-21 Psma Development Company, Llc Biomarkers for psma targeted therapy for prostate cancer
ES2978993T3 (es) 2014-02-21 2024-09-23 Ibc Pharmaceuticals Inc Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
DK3151865T3 (da) 2014-05-22 2021-10-25 Byondis Bv Stedsspecifik konjugation af linker medicin til antistof og resulterende adcs
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
CA2961774C (en) 2014-10-07 2023-05-23 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US10155820B2 (en) 2014-11-12 2018-12-18 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
CN104447955B (zh) * 2014-11-23 2018-04-20 南京市第一医院 一种与psma膜外区靶向性结合的多肽及其应用
EP3064507A1 (en) 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
CA2979976A1 (en) 2015-03-17 2016-09-22 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
WO2016149485A1 (en) 2015-03-17 2016-09-22 The Regents Of The University Of California Novel chemoimmunotherapy for epithelial cancer
AU2016252771B2 (en) 2015-04-22 2021-12-16 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
EP3932428A1 (en) 2015-05-21 2022-01-05 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
CN115960230A (zh) 2015-08-07 2023-04-14 伊麦吉纳博公司 靶向分子的抗原结合构建体
EP3192810A1 (en) * 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
IL263102B2 (en) 2016-05-20 2023-11-01 Harpoon Therapeutics Inc A serum albumin-binding protein with a single site
LT3461261T (lt) 2016-05-20 2025-08-25 Harpoon Therapeutics, Inc. Vienos grandinės kintamo fragmento cd3 surišantys baltymai
ES2965349T3 (es) 2016-06-06 2024-04-12 Abzena Uk Ltd Anticuerpos, usos de los mismos y conjugados de los mismos
GB201614162D0 (en) 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
KR20190087539A (ko) 2016-11-23 2019-07-24 하푼 테라퓨틱스, 인크. Psma 표적화 삼중특이성 단백질 및 사용 방법
US10849973B2 (en) 2016-11-23 2020-12-01 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
KR102376863B1 (ko) 2017-05-12 2022-03-21 하푼 테라퓨틱스, 인크. 메소텔린 결합 단백질
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
CN111630070B (zh) 2017-10-13 2024-07-30 哈普恩治疗公司 三特异性蛋白质及使用方法
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CA3079759C (en) 2017-11-04 2025-10-07 Sona Nanotech Inc. Metallic Nanoparticles and Their Production Processes
EP3762410A4 (en) 2018-03-06 2022-04-06 The Trustees of the University of Pennsylvania CHEMICAL PROSTATE MEMBRANE SPECIFIC ANTIGEN SPECIFIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF
HUE068337T2 (hu) * 2018-03-29 2024-12-28 Ambrx Inc Humanizált, prosztataspecifikus membránantigén (PSMA) elleni ellenanyag-hatóanyag konjugátumok
AU2019271138A1 (en) 2018-05-14 2021-01-07 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
EP3587454A1 (en) * 2018-06-27 2020-01-01 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen
HRP20230115T1 (hr) 2018-07-31 2023-06-09 Heidelberg Pharma Research Gmbh Humanizirana antitijela protiv psma
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
USD925928S1 (en) 2019-03-01 2021-07-27 Simplehuman, Llc Vanity mirror
WO2021168303A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
EP4178624A2 (en) 2020-07-07 2023-05-17 Bionecure Therapeutics, Inc. Maytansinoids as adc payloads and their use for the treatment of cancer
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
CN112285082A (zh) * 2020-10-28 2021-01-29 上海睿钰生物科技有限公司 一种基于细胞直径评价细胞杀伤效力的方法及其应用
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
JPWO2022239720A1 (enExample) 2021-05-10 2022-11-17
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2024186656A1 (en) 2023-03-03 2024-09-12 Arsenal Biosciences, Inc. Systems targeting psma and ca9

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454106A (en) 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4824986A (en) 1985-04-26 1989-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metal chelate protein conjugate
US4814275A (en) * 1985-05-13 1989-03-21 E.I. Dupont De Nemours And Company Monoclonal hybridoma antibody specific for a human epithelial antigen
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4863854A (en) * 1985-08-12 1989-09-05 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to mucin-like human differentiation antigens
DE3684578D1 (de) * 1985-12-17 1992-04-30 Eastern Virginia Medical Autho Monoklonale antikoerper mit bindungsspezifitaet fuer menschliche prostatatumorantigene und methoden fuer ihre verwendung.
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
EP0232751B1 (en) 1986-01-23 1991-09-11 E.R. Squibb & Sons, Inc. 1-substituted-4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
MX174467B (es) 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
DK172629B1 (da) 1986-02-14 1999-03-22 Nihon Mediphysics Co Ltd Reaktive højmolekylære forbindelser med mindst én fri aminogruppe, højmolekylære forbindelser kombineret med et fysiologisk
AU8152887A (en) 1986-10-17 1988-05-06 Cytogen Corporation Method for preparation of protein-chelator-metal ion compositions suitable for injection
US4863851A (en) * 1986-10-20 1989-09-05 The Upjohn Company Monoclonal antibody to prostate secretory protein
US5057302A (en) 1987-02-13 1991-10-15 Abbott Laboratories Bifunctional chelating agents
MX171769B (es) 1987-02-16 1993-11-15 Sumitomo Chemical Co Base catalitica solida y procedimiento para obtenerla
US5013645A (en) * 1987-04-14 1991-05-07 Abbott Laboratories Immunological methods and materials for detection of tumor associated antigens
GB9007965D0 (en) 1990-04-09 1990-06-06 Nycomed As Compounds
US5531978A (en) 1987-07-16 1996-07-02 Nycomed Imaging As Aminopolycarboxylic acids and derivatives thereof
DE3869251D1 (de) 1987-07-16 1992-04-23 Nycomed As Aminopolycarbonsaeure und ihre derivate.
AU619218B2 (en) 1987-11-06 1992-01-23 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5217704A (en) 1987-11-06 1993-06-08 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5130118A (en) 1987-11-06 1992-07-14 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5342924A (en) * 1987-12-31 1994-08-30 Tanox Biosystems, Inc. Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor
GB8801646D0 (en) 1988-01-26 1988-02-24 Nycomed As Chemical compounds
US5229289A (en) * 1988-03-11 1993-07-20 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5118611A (en) * 1988-07-25 1992-06-02 Adeza Biomedical Corporation Adenocarcinoma antigen binding methods and reagents
ATE133165T1 (de) 1989-02-10 1996-02-15 Celltech Therapeutics Ltd Aza-macrozyklen und verfahren zu deren herstellung
US5053503A (en) 1989-02-17 1991-10-01 Centocor Chelating agents
DE3911816A1 (de) 1989-04-11 1990-10-25 Hoechst Ag Substituierte 1,4,7,10-tetraazacyclotridecane, verfahren zu deren herstellung sowie verwendung derselben zur markierung von substanzen mit radionukliden
US5244816A (en) 1989-10-11 1993-09-14 Akzo N.V. Method for purifying chelator conjugated compounds
EP0453554A4 (en) 1989-11-13 1993-02-17 Xoma Corporation Chimeric mouse human antibodies with specificity to hiv antigens
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9115192D0 (en) 1991-07-12 1991-08-28 Antisoma Ltd Cancer treatment
US5227471A (en) * 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6036955A (en) 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5489525A (en) * 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
EP1757694A3 (en) 1992-11-05 2008-02-27 Sloan Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5428156A (en) 1993-04-02 1995-06-27 Associated Universities, Inc. Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging
CA2163107C (en) 1993-05-17 2001-04-17 David Milton Goldenberg Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
US5935818A (en) 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
US5599677A (en) * 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
WO1995026206A1 (en) 1994-03-28 1995-10-05 The Regents Of The University Of California Method for preparing radionuclide-labeled chelating agent-ligand complexes
US6693190B1 (en) 1994-05-11 2004-02-17 Bracco International B.V. Enhanced relaxivity monomeric and multimeric compounds
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
JP2001526522A (ja) 1995-02-24 2001-12-18 スローン−ケタリング・インスティテュート・フォー・キャンサー・リサーチ 前立腺特異的膜抗原およびその使用
US5773292A (en) 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
JPH11507046A (ja) 1995-06-07 1999-06-22 イムノメディクス，インコーポレイテッド 診断剤および治療剤の標的部位への改良された送達方法
IT1283218B1 (it) 1996-03-08 1998-04-16 Bracco Spa Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi
US6962981B1 (en) * 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6150508A (en) 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
ATE318147T1 (de) 1996-03-25 2006-03-15 Medarex Inc Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US5804602A (en) 1996-06-17 1998-09-08 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5958474A (en) 1996-08-21 1999-09-28 Nestec S.A. Process for preparing food flavor precursors
IT1291623B1 (it) 1997-04-18 1999-01-11 Bracco Spa Procedimento per la coniugazione di chelanti con molecole contenenti gruppi amminici
WO1999043710A1 (en) 1998-02-26 1999-09-02 Beckman Coulter, Inc. Prostate-specific membrane antigens and methods of making and using
WO2000050457A1 (en) 1999-02-22 2000-08-31 Beckman Coulter, Inc. Prostate-specific membrane antigens and methods of making and using
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
CA2374001A1 (en) 1999-06-07 2000-12-14 Center For Molecular Medicine And Immunology Alpha or beta emitters attached to fragments in radioimmunotherapy
AU2002211232B2 (en) 2000-09-15 2006-10-19 Sloan Kettering Institute For Cancer Research Targeted alpha particle therapy using actinium-225 conjugates
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
JP4619651B2 (ja) 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用

Also Published As

Publication number Publication date
ATE319089T1 (de) 2006-03-15
US20030003101A1 (en) 2003-01-02
NZ524036A (en) 2004-12-24
EA199900033A1 (ru) 1999-08-26
CN1244921A (zh) 2000-02-16
EP0956506A4 (en) 2002-07-10
IL162230A (en) 2010-11-30
IL127979A0 (en) 1999-11-30
CA2261018C (en) 2008-06-03
EP0956506B1 (en) 2006-03-01
JP2009197002A (ja) 2009-09-03
EP1655605A3 (en) 2006-08-30
BR9710487A (pt) 1999-08-17
DE69735368T2 (de) 2006-08-03
EP0956506A1 (en) 1999-11-17
US7666425B1 (en) 2010-02-23
AU733544C (en) 2003-10-16
JP2002513378A (ja) 2002-05-08
JP4503102B2 (ja) 2010-07-14
CN1673744A (zh) 2005-09-28
PT956506E (pt) 2006-05-31
EA004634B1 (ru) 2004-06-24
AU3797697A (en) 1998-02-10
DE69735368D1 (de) 2006-04-27
JP5627191B2 (ja) 2014-11-19
US7112412B1 (en) 2006-09-26
WO1998003873A1 (en) 1998-01-29
CN100344970C (zh) 2007-10-24
US6107090A (en) 2000-08-22
EP1655605A2 (en) 2006-05-10
HK1025631A1 (en) 2000-11-17
NZ333683A (en) 2001-09-28
EA200400179A1 (ru) 2004-06-24
IL162230A0 (en) 2005-11-20
AU733544B2 (en) 2001-05-17
ES2255723T3 (es) 2006-07-01
CA2261018A1 (en) 1998-01-29

Similar Documents

Publication Publication Date Title
CN1165764C (zh) 抗psma抗体或其抗原结合部分，以及它们的用途
CN1229391C (zh) 涉及α6β4整联蛋白的人胃肠上皮肿瘤抗原的抗体
CN1201005C (zh) 特异性检测癌细胞的抗原结合片段、编码所述片段的dna、以及它们在预防和检测癌症上的用途
CN1173991C (zh) 作为血管内皮生长因子受体的f1k-1
CN1413220A (zh) 抗前列腺干细胞抗原(psca)抗体组合物及其应用方法
CN1630529A (zh) 用于诊断和治疗b细胞恶性肿瘤的b细胞淋巴瘤特异性抗原
CN1761482A (zh) 与胰腺癌相关的抗原、针对它的抗体以及诊断和治疗方法
CN1826138A (zh) Rg1抗体及其用途
CN1596313A (zh) 人源化的胶原抗体及相关方法
WO1998003873A9 (en) Treatment and diagnosis of cancer
CN1646910A (zh) 白血病、前白血病或非白血病性恶性血液疾病的判定方法以及诊断药
CN1809592A (zh) 识别n－乙醇酰gm3神经节苷脂的重组抗体和片段以及其在肿瘤诊断和治疗上的应用
CN1771338A (zh) 高亲和力抗人类IgE抗体
CN1761683A (zh) 癌症疾病改善抗体
CN1662254A (zh) Alcam和alcam调制剂
CN1849137A (zh) 基于vefg,her－2,psa蛋白质异构体的用于诊断和治疗的疾病的特效试剂
CN1606569A (zh) 具有mn结合和细胞粘附中和活性的人类抗体
CN1551783A (zh) 治疗多发性骨髓瘤的方法
CN101076542A (zh) 特异性针对肝细胞癌和其他癌的抗体及其用途
CN1642983A (zh) 抗C5aR抗体及其应用
CN101490088A (zh) 用于靶向hepsin的方法和组合物
CN1151184A (zh) 对细胞周期非依赖的神经胶质瘤表面抗原特异的人单克隆抗体
CN1279056C (zh) 肿瘤相关抗原sm5－1的特异性抗体及其应用
HK1025631B (en) Antibody against psma or antigen binding portion thereof, as well as their use
CN1961004A (zh) 作为潜在抗肿瘤治疗剂的单克隆抗体sc104及其特异性结合至唾液酸丁糖基碳水化合物的衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20040908